FDA's stand on Provenge riles cancer patients

The FDA's decision to demand more data on Dendreon's cancer drug Provenge--after an advisory committee had recommended approval--has energized a host of prostate cancer patients. Advocacy groups have been raising their voices to protest--and in some cases make death threats--over what they see as a last hope for late-stage prostate cancer. Doctors have joined their voices to the chorus and some lawmakers have called for a probe of the decision. Regulators say there's no proof that it works. Patients say it's their only hope to add a couple of months to their lives.

- read the article from the Los Angeles Times

Related Articles:
Congressmen want closer look at Provenge delay. Report
Think tank asks FDA to purge conflicts. Report
Provenge delay triggers furor among cancer victims. Report
Dendreon gets approvable letter for Provenge. Report